سعر كليروسواب 13.9% كريم 30 جم 2022

Eflornithine 13.9% topical cream 30 gm by Uniswab (Egypt) for reduction of unwanted facial hair in women.

• Reduction of unwanted facial hair in women; studied on the face and adjacent areas under the chin only (US VANIQA).Population: Women (US label); safety/effectiveness not established <12 yearsDailyMed (U.S. NLM)

• Most frequent treatment-related AEs: acne, pseudofolliculitis barbae, stinging, burning, dry skin, pruritus, erythema, tingling; usually mild (US VANIQA clinical experience).International label, equivalent formulation · DailyMed (U.S. NLM)

• Contraindicated in patients with a history of sensitivity to any components of the preparation (US VANIQA).International label, equivalent formulation · DailyMed (U.S. NLM)

• For external use only; discontinue if hypersensitivity; transient stinging/burning may occur on abraded skin; not a depilatory — continue hair removal; hair growth may return toward pretreatment levels within ~8 weeks after stopping; if irritation persists reduce frequency or stop (US VANIQA).International label, equivalent formulation · DailyMed (U.S. NLM)

• US historical Pregnancy Category C labeling on VANIQA; no adequate well-controlled studies in pregnant women; weigh risk/benefit carefully — consider not implementing or discontinuing use in pregnancy (US label).International label, equivalent formulation · DailyMed (U.S. NLM)
• Unknown whether eflornithine hydrochloride is excreted in human milk; caution in nursing women (US VANIQA).International label, equivalent formulation · DailyMed (U.S. NLM)

• Eflornithine: Irreversibly inhibits skin ornithine decarboxylase (ODC), reducing polyamine synthesis and slowing hair growth (US VANIQA label).